Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of single-dose QP-6211 injection for postoperative analgesia
CTR20263513Phase 2Active
- Sponsor
- ClearPoint Biotech
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QP-6211 in postoperative pain, sponsored by ClearPoint Biotech. Started Sep 2026; status: active.
02
Drugs
QP-6211
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20263513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263513.